Navigation Links
Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/17/2007

SOUTH SAN FRANCISCO, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that the company will present data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference will be held October 22-26, 2007 in San Francisco, California.

Preliminary data from Sunesis' ongoing Phase 2 clinical trial of the company's lead candidate, SNS-595, in platinum-resistant ovarian cancer will be featured in a poster session on Tuesday, October 23, 2007. In addition, the company will present non-clinical data on SNS-595's in vivo activity in combination with standard chemotherapies, and on SNS-032, the company's cyclin-dependent kinase (CDK) inhibitor, currently in development for hematologic malignancies.

Tuesday, October 23, 2007

* Poster Session A - Clinical Trials

Abstract No. A158

A Phase 2 trial of SNS-595 in women with platinum refractory epithelial

ovarian cancer

* Poster Session A -Small Molecule Therapeutic Agents: Kinase Inhibitors

Abstract No. A258

SNS-032 has potent anti-tumor activity in vivo against human leukemia

and multiple myeloma xenografts

Wednesday, October 24, 2007

* Poster Session B - Other Small Molecule Therapeutics

Abstract No. B285

SNS-595 potentiates the in vivo anti-tumor activity of carboplatin,

cisplatin and gemcitabine in solid tumor xenografts

All posters will be presented in the Moscone Convention Center West Exhibit Hall and will also be available following the conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. SNS-595, a replication-dependent DNA damaging agent, is currently in two Phase 1b acute leukemia clinical trials and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is currently being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... San Francisco, CA (PRWEB) , ... February 04, ... ... future of enterprise talent development and compliance training, today announced an interactive ... on Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. ... editing, announced today that Edward Lanphier , Sangamo,s ... on the progress of Sangamo,s ZFP Therapeutic ® ... strategy at 2:40 pm ET on Thursday, February 11, ... Global Healthcare Conference. The conference is being held in ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Digital Forensics Club, takes place February 5-6 at the University’s student center, ... and activities such as workshops and competitions for ample networking, learning and ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
Breaking Biology News(10 mins):